ABSTRACT
Introduction Omega-3 long chain polyunsaturated fatty acids (LCPUFA) have been associated with a reduction in risk for preterm birth. However, there is limited understanding of how fatty acids and their bioactive derivatives (oxylipins) change over the course of pregnancy. Here we document the changes in concentration of fatty acids and oxylipins during pregnancy and how fatty acid status and oxylipin concentrations are affected by supplementation with omega-3 LCPUFA. We also investigate the degree to which fatty acid and oxylipin changes across pregnancy are influenced by baseline omega-3 status.
Materials and Methods We profiled the fatty acids in all lipids in dried blood spots (total blood fatty acids) by gas chromatography and free (unesterified) fatty acids and their associated oxylipins in separate dried blood spot samples by LC-MS-MS collected from a random sample of 1263 women with a singleton pregnancy who participated in the ORIP (Omega-3 fats to Reduce the Incidence of Prematurity) trial. ORIP is a double-blind, randomized controlled trial involving 5544 participants and designed to determine the effect of supplementing the diets of pregnant women with omega-3 LCPUFA on the incidence of early preterm birth. Maternal whole blood finger prick samples were collected at baseline (∼14 weeks gestation) and at completion of the study intervention period (34 weeks gestation).
Results The concentration of most total and free polyunsaturated fatty acids and their associated oxylipins declined over the course of pregnancy. Omega-3 LCPUFA supplementation increased total DHA and 7-HDHA and mitigated the decline in free DHA, 4-HDHA and 14-HDHA. The intervention had minimal or no effect on free EPA, LA, AA and their associated oxylipins. Omega-3 LCPUFA supplementation in women with higher omega-3 status at baseline was associated with a significant increase in 7-HDHA and 4-HDHA between the treatment and control whereas there were no differences between groups in 7-HDHA and 4-HDHA in women with intermediate or lower baseline omega-3 status.
Conclusion Our data suggest a differential response with or without omega-3 supplementation for DHA and DHA-derived oxylipins, which may have an important role to play in modulating pregnancy duration. Further work is needed to understand their role, which may allow us to better tailor omega-3 supplementation for preterm birth prevention.
Competing Interest Statement
Dr. Gibson received supplies from Croda UK, prepared supplies for the ORIP trial for Efamol/Wassen UK. Dr Gibson and Dr Liu hold a patent (WO2013/10 40 25 A1) on stabilizing and analyzing fatty acids in a biologic sample stored on solid media, owned by Adelaide Research and Innovation, the University of Adelaide, and licensed to Xerion. Dr. Makrides received supplies from Croda UK, and prepared supplies for the ORIP trial for Efamol/Wassen UK. Dr. Best, Dr Yelland, Dr Leemaqz and Dr. Gomersall have no conflicts of interest to disclose.
Clinical Protocols
https://bmjopen.bmj.com/content/bmjopen/7/9/e018360.full.pdf
Funding Statement
The original study was supported by grants from the National Health and Medical Research Council (NHMRC) (1050468), the Thyne Reid Foundation and fellowships awarded to M Makrides (1061704), RA Gibson (1046207) and LN Yelland (1052388) from the NHMRC. The secondary analysis was supported by the National Health and Medical Research Council Centre of Research Excellence in Targeted Nutrition to Improve Maternal and Child Health Outcomes (1135155). KP Best was supported by a Women's and Children's Hospital Foundation, MS McLeod Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all participants in the original study and all procedures were conducted in accordance with the approval of the relevant Human Research Ethics Committees (HREC) at the six sites involved in the multi-centre trial. The HREC at the lead study site was the Women's and Children's Health Network Human Research Ethics Committee, which provided approval (HREC/13/WCHN/10) on 1 May 2013 for the original study and the analysis reported in the present paper.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available to Researchers who provide a methodologically sound research proposal following review and approval by the trial steering committee and completion of a signed data access agreement. Following approval, de-identified, individual participant data that underlie the results reported in this article (text, tables, figures and appendices) and/or dataset(s) will be limited to those participants and variables that are necessary for completion of the approved research proposal. Data sharing requests for de-identified raw data should be made to the trial steering committee and can be submitted to maria.makrides{at}sahmri.com or karen.best{at}sahmri.com
Abbreviations used
- AA
- arachidonic acid
- ALA
- alpha linolenic acid
- DBS
- dried blood spot
- DHA
- docosahexaenoic acid
- DPA
- docosapentaenoic acid
- EPA
- eicosapentaenoic acid
- FAME
- fatty acid methyl esters
- LA
- linolenic acid
- LC-MS-MS
- Liquid Chromatography with tandem mass spectrometry
- LCPUFA
- long chain polyunsaturated fatty acid
- ORIP
- Omega-3 fats to Reduce the Incidence of Prematurity
- PUFA
- polyunsaturated fatty acids.
